预测非小细胞肺癌免疫治疗疗效生物标志物的研究前沿与热点分析

Frontier and hotspot of biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer

目的分析预测非小细胞肺癌免疫治疗疗效生物标志物研究的发展现状,为后续研究提供参考。方法计算机检索Web of Science核心合集2017—2021年收录的预测非小细胞肺癌免疫治疗疗效的生物标志物研究。通过CiteSpace对该领域文献的年度分布、期刊、作者、国家、机构、关键词等进行可视化分析。结果共纳入426篇文献,包括298篇论著、128篇综述。年平均发文量约为85篇,发文量呈逐年增加趋势。细胞程序性死亡配体1(PD-L1)表达、肿瘤突变负荷、肿瘤微环境、液体活检等为该领域的热点关键词。结论未来将液体活检、肿瘤微环境生物标志物与影像组学分析联合起来,对非小细胞肺癌患者体内淋巴细胞的免疫状态以及病灶特征等肿瘤相关信息进行更加精准的评估可能是该领域的研究热点及前沿。

Objective To analyze the current development of researches on biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer and to provide reference for subsequent studies.Methods Studies on biomarkers for predicting the efficacy of immunotherapy for non-small cell lung cancer indexed in the Web of Science Core Collection from 2017 to 2021 were searched by computer.The annual distribution,journals,authors,countries,institutions,and keywords of studies were visualized and analyzed by CiteSpace.Results A total of 426 studies were collected,including 298 articles and 128 reviews.The average number of published studies was about 85,and increased year by year.PD-L1 expression,tumor mutational burden,tumor microenvironment and liquid biopsy were hot keywords in this field.Conclusion In the future,combination of biomarkers in the liquid biopsy and tumor microenvironment with radiomics analysis will be the research hotspot and frontier in this field for more accurate assessment with tumorrelated signatures such as lymphocytic immune status and characteristics of tumor lesions in non-small cell lung cancer patients.